-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241

Benzinga·10/19/2026 13:26:44
Listen to the news
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $241.